Novel Insights into Interstitial Lung Disease Diagnostics and Treatment
A special issue of Journal of Respiration (ISSN 2673-527X).
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 3327
Special Issue Editors
Interests: interstitial lung diseases; idiopathic pulmonary fibrosis; sarcoidosis
Interests: interstitial lung diseases; idiopathic pulmonary fibrosis; autoimmune diseases
Special Issue Information
Dear Colleagues,
In recent years, interstitial lung diseases (ILD) have presented an amazing development. The different international consensus have made it possible to clarify the different types of ILDs and optimal therapies, especially for idiopathic pulmonary fibrosis (IPF). Recent clinical trials have permitted the use of nintedanib and pirfenidone to reduce the progression of fibrotic disease. Additionally, the development of new techniques (e.g., cryobiopsy) and the multidisciplinary discussion have been definitive in the progress of diagnosis accuracy. However, many areas are currently in development. The study of different biologic pathways involved in pulmonary fibrosis is currently under investigation and new drugs are being tested. The development of the “fibrotic pulmonary phenotype“ definition in recent years and the beneficial effects of antifibrotics in this group has been one of the main recent advances in the field. This recent research has brought the ILD field into a novel and exciting moment. This Special Issue of Journal of Respiration aims to bring together current research and opinions on new concepts in diagnosis and treatment of interstitial lung diseases.
Dr. Jacobo Sellarés-Torres
Dr. Fernanda Hernandez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Respiration is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- interstitial lung diseases
- pulmonary fibrosis
- antifibrotic therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.